Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease. 2022

Xinnan Li, and Tiantian Li, and Feiyan Zhan, and Feiyue Cheng, and Li Lu, and Bocheng Zhang, and Junda Li, and Zhaoxin Hu, and Shengnan Zhou, and Yilin Jia, and Stephanie Allen, and Lisa White, and James Phillips, and Zheying Zhu, and Jinyi Xu, and Hequan Yao
State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China.

Based on a multitarget strategy, a series of novel chromanone-1-benzyl-1,2,3,6-tetrahydropyridin hybrids were identified for the potential treatment of Alzheimer's disease (AD). Biological evaluation demonstrated that these hybrids exhibited significant inhibitory activities toward acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B). The optimal compound C10 possessed excellent dual AChE/MAO-B inhibition both in terms of potency and equilibrium (AChE: IC50 = 0.58 ± 0.05 μM; MAO-B: IC50 = 0.41 ± 0.04 μM). Further molecular modeling and kinetic investigations revealed that compound C10 was a dual-binding inhibitor bound to both the catalytic anionic site and peripheral anionic site of AChE. In addition, compound C10 exhibited low neurotoxicity and potently inhibited AChE enzymatic activity. Furthermore, compound C10 more effectively protected against mitochondrial dysfunction and oxidation than donepezil, strongly inhibited AChE-induced amyloid aggregation, and moderately reduced glutaraldehyde-induced phosphorylation of tau protein in SH-SY5Y cells. Moreover, compound C10 displayed largely enhanced improvements in cognitive behaviors and spatial memory in a scopolamine-induced AD mice model with better efficacy than donepezil. Overall, the multifunctional profiles of compound C10 suggest that it deserves further investigation as a promising lead for the prospective treatment of AD.

UI MeSH Term Description Entries
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D002867 Chromones 1,4-Benzopyrones,Chromone,1,4 Benzopyrones
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000110 Acetylcholinesterase An enzyme that catalyzes the hydrolysis of ACETYLCHOLINE to CHOLINE and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. Acetylcholine Hydrolase,Acetylthiocholinesterase,Hydrolase, Acetylcholine
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Xinnan Li, and Tiantian Li, and Feiyan Zhan, and Feiyue Cheng, and Li Lu, and Bocheng Zhang, and Junda Li, and Zhaoxin Hu, and Shengnan Zhou, and Yilin Jia, and Stephanie Allen, and Lisa White, and James Phillips, and Zheying Zhu, and Jinyi Xu, and Hequan Yao
August 2023, Drug development research,
Xinnan Li, and Tiantian Li, and Feiyan Zhan, and Feiyue Cheng, and Li Lu, and Bocheng Zhang, and Junda Li, and Zhaoxin Hu, and Shengnan Zhou, and Yilin Jia, and Stephanie Allen, and Lisa White, and James Phillips, and Zheying Zhu, and Jinyi Xu, and Hequan Yao
November 2022, European journal of medicinal chemistry,
Xinnan Li, and Tiantian Li, and Feiyan Zhan, and Feiyue Cheng, and Li Lu, and Bocheng Zhang, and Junda Li, and Zhaoxin Hu, and Shengnan Zhou, and Yilin Jia, and Stephanie Allen, and Lisa White, and James Phillips, and Zheying Zhu, and Jinyi Xu, and Hequan Yao
October 2021, Bioorganic & medicinal chemistry letters,
Xinnan Li, and Tiantian Li, and Feiyan Zhan, and Feiyue Cheng, and Li Lu, and Bocheng Zhang, and Junda Li, and Zhaoxin Hu, and Shengnan Zhou, and Yilin Jia, and Stephanie Allen, and Lisa White, and James Phillips, and Zheying Zhu, and Jinyi Xu, and Hequan Yao
September 2019, European journal of medicinal chemistry,
Xinnan Li, and Tiantian Li, and Feiyan Zhan, and Feiyue Cheng, and Li Lu, and Bocheng Zhang, and Junda Li, and Zhaoxin Hu, and Shengnan Zhou, and Yilin Jia, and Stephanie Allen, and Lisa White, and James Phillips, and Zheying Zhu, and Jinyi Xu, and Hequan Yao
July 2018, Bioorganic & medicinal chemistry,
Xinnan Li, and Tiantian Li, and Feiyan Zhan, and Feiyue Cheng, and Li Lu, and Bocheng Zhang, and Junda Li, and Zhaoxin Hu, and Shengnan Zhou, and Yilin Jia, and Stephanie Allen, and Lisa White, and James Phillips, and Zheying Zhu, and Jinyi Xu, and Hequan Yao
March 2021, European journal of medicinal chemistry,
Xinnan Li, and Tiantian Li, and Feiyan Zhan, and Feiyue Cheng, and Li Lu, and Bocheng Zhang, and Junda Li, and Zhaoxin Hu, and Shengnan Zhou, and Yilin Jia, and Stephanie Allen, and Lisa White, and James Phillips, and Zheying Zhu, and Jinyi Xu, and Hequan Yao
June 2019, MedChemComm,
Xinnan Li, and Tiantian Li, and Feiyan Zhan, and Feiyue Cheng, and Li Lu, and Bocheng Zhang, and Junda Li, and Zhaoxin Hu, and Shengnan Zhou, and Yilin Jia, and Stephanie Allen, and Lisa White, and James Phillips, and Zheying Zhu, and Jinyi Xu, and Hequan Yao
February 2018, MedChemComm,
Xinnan Li, and Tiantian Li, and Feiyan Zhan, and Feiyue Cheng, and Li Lu, and Bocheng Zhang, and Junda Li, and Zhaoxin Hu, and Shengnan Zhou, and Yilin Jia, and Stephanie Allen, and Lisa White, and James Phillips, and Zheying Zhu, and Jinyi Xu, and Hequan Yao
November 2021, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Xinnan Li, and Tiantian Li, and Feiyan Zhan, and Feiyue Cheng, and Li Lu, and Bocheng Zhang, and Junda Li, and Zhaoxin Hu, and Shengnan Zhou, and Yilin Jia, and Stephanie Allen, and Lisa White, and James Phillips, and Zheying Zhu, and Jinyi Xu, and Hequan Yao
December 2021, Journal of enzyme inhibition and medicinal chemistry,
Copied contents to your clipboard!